
    
      A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study in Healthy East Asian and
      Caucasian Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of
      Single and Multiple Ascending Oral Doses of TG-2349, and Followed by a Dose-Ranging Study in
      Hepatitis C Genotype 1 Infected Patients.
    
  